Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences
G Bondolfi, C Lissner, M Kosel, CB Eap… - International Journal …, 2000 - academic.oup.com
In an open trial 11 in-patients with a major depressive episode (ICD-10), extensive
metabolizers of mephenytoin (CYP2C19) and dextromethorphan (CYP2D6) and who were …
metabolizers of mephenytoin (CYP2C19) and dextromethorphan (CYP2D6) and who were …
An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir
MM Gutierrez, J Rosenberg, W Abramowitz - Clinical therapeutics, 2003 - Elsevier
Background: Depression often coexists with a number of disease states, and patients with a
diagnosis of depression often receive multiple medications. Thus, it is desirable to avoid …
diagnosis of depression often receive multiple medications. Thus, it is desirable to avoid …
[HTML][HTML] Escitalopram population pharmacokinetics and remedial strategies based on CYP2C19 phenotype
X Liu, G Ju, X Huang, W Yang, L Chen, C Li… - Journal of Affective …, 2024 - Elsevier
Background and purpose CYP2C19 is a key factor influencing escitalopram (SCIT)
exposure. However, different studies reported various results. This study aims to develop a …
exposure. However, different studies reported various results. This study aims to develop a …
Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients
I Rudberg, B Mohebi, M Hermann… - Clinical …, 2008 - Wiley Online Library
Recently, a novel allelic variant of cytochrome P450 2C19 encoding ultrarapid enzyme
activity was described (denoted CYP2C19* 17). The objective of this study was to evaluate …
activity was described (denoted CYP2C19* 17). The objective of this study was to evaluate …
A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges
TP McLaughlin, MT Eaddy, AN Grudzinski - Clinical therapeutics, 2004 - Elsevier
Background: Citalopram, a selective serotonin reuptake inhibitor (SSRI) recently approved
in the United States for treatment of depression, has similar efficacy to and a lower …
in the United States for treatment of depression, has similar efficacy to and a lower …
Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients
Objective: The antidepressant escitalopram is predominantly metabolized by the
polymorphic CYP2C19 enzyme. The authors investigated the effect of CYP2C19 genotype …
polymorphic CYP2C19 enzyme. The authors investigated the effect of CYP2C19 genotype …
Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation
G Bondolfi, C Chautems, B Rochat, G Bertschy… - …, 1996 - Springer
The effect of comedication with fluvoxamine on the plasma concentrations of the
enantiomers of citalopram and its metabolites in dextromethorphan/mephenytoin …
enantiomers of citalopram and its metabolites in dextromethorphan/mephenytoin …
Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder
L Schmitt, B Tonnoir, C Arbus - Neuropsychobiology, 2007 - karger.com
The objective of this open-label, multicentre study was to evaluate the safety and efficacy of
treatment with escitalopram (10 or 20 mg/day) for 6 weeks following a switch from …
treatment with escitalopram (10 or 20 mg/day) for 6 weeks following a switch from …
Faster onset of antidepressant effects of citalopram compared with sertraline in drug-naive first-episode major depressive disorder in a Chinese population: a 6-week …
JW Hsu, TP Su, CY Huang, YS Chen… - Journal of clinical …, 2011 - journals.lww.com
Several previous studies, including a meta-analysis, reported no significant differences
between various selective serotonin reuptake inhibitors (SSRIs) in the treatment of major …
between various selective serotonin reuptake inhibitors (SSRIs) in the treatment of major …
Serum concentrations of citalopram–dose-dependent variation in R-and S-enantiomer ratios
L Tanum, LP Strand, H Refsum - Pharmacopsychiatry, 2010 - thieme-connect.com
Introduction: The antidepressive effect of racemic citalopram (CIT) is exerted by S-CIT, while
R-CIT is a partial antagonist to S-CIT. Since R-and S-CIT are metabolized by different …
R-CIT is a partial antagonist to S-CIT. Since R-and S-CIT are metabolized by different …